Amikacin Liposome Inhalation Suspension for Refractory MAC Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-Term Exposure.

Like Comment
In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobacterium avium complex (MAC) lung disease (ALIS+GBT, 29% [65/224] vs GBT-alone, 8.9% [10/112], P

View the full article @ Chest

Get PDF with LibKey
Authors: David E Griffith, Rachel Thomson, Patrick A Flume, Timothy R Aksamit, Stephen K Field, Doreen J Addrizzo-Harris, Kozo Morimoto, Wouter Hoefsloot, Kevin C Mange, Dayton W Yuen, Monika Ciesielska, Richard J Wallace, Jakko van Ingen, Barbara A Brown-Elliott, Chris Coulter, Kevin L Winthrop, CONVERT Study Group


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following